Results 51 to 60 of about 216,693 (188)

Treatment options for C3 glomerulopathy [PDF]

Current Opinion in Nephrology and Hypertension, 2013
The purpose of this review is to discuss emerging nomenclature, review the salient clinicopathological features and describe the therapeutic options available for the treatment of C3 glomerulopathy (C3G).C3G is minimally responsive to traditional immune suppression and randomized controlled trials to support therapy are absent.
Carla M, Nester, Richard J, Smith
openaire   +2 more sources

Effectiveness of Cyclosporine in a 10-year-old Girl with C3 Glomerulopathy [PDF]

Childhood Kidney Diseases, 2017
C3 glomerulopathy (C3G) is a recently defined pathological entity characterized by C3 accumulation with absent or scant immunoglobulin deposition, leading to variable glomerular inflammation.
Kyung Mi Jang, Yong Hoon Park
doaj   +1 more source

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

Rethinking Common Diagnoses: Idiopathic Multicentric Castleman Disease Presenting as TAFRO Syndrome: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT Idiopathic multicentric Castleman disease (TAFRO subtype) can mimic common differentials. High suspicion is required for chronic systemic symptoms and generalized lymphadenopathy. As fine‐needle aspiration is often non‐diagnostic, early excisional biopsy is important.
Divita Rohatgi, Annesha Chakraborty, Sourav Kumar, Anurag Rohatgi   +3 more
wiley   +1 more source

Phenotypic and Genotypic Landscape of Sitosterolemia in China: Including a Rare Case With Nephronophthisis

Molecular Genetics &Genomic Medicine, Volume 14, Issue 9, September 2026.
This study describes the first reported case of concurrent sitosterolemia (STSL) and nephronophthisis (NPHP). Additionally, we provide a systematic review of the clinical and genetic characteristics of Chinese STSL patients, representing the largest comprehensive cohort in China to date.
Dan Ding, Hongmei Wu, Fei Zhao, Bixia Zheng, Qiuxia Chen   +4 more
wiley   +1 more source

Successful Control of Late‐Onset Nephrotic Syndrome in FN1‐Associated Fibronectin Glomerulopathy: A 17‐Year Clinical Course

Nephrology, Volume 31, Issue 9, September 2026.
ABSTRACT Fibronectin glomerulopathy (FNG) is a rare renal disorder characterized by excessive glomerular fibronectin deposition, often associated with variants in the fibronectin 1 (FN1) gene. Clinically, FNG presents with proteinuria, hematuria, and hypertension, and may progress to end‐stage kidney disease.
Nobuhiro Kanazawa, Masayuki Iyoda, Kazuki Abe, Taihei Suzuki, Yoko Shirai, Kenichiro Miura, Kazuho Honda, Hirokazu Honda   +7 more
wiley   +1 more source

Complement Inhibitors in Clinical Trials for Glomerular Diseases

Frontiers in Immunology, 2019
Defective complement action is a cause of several human glomerular diseases including atypical hemolytic uremic syndrome (aHUS), anti-neutrophil cytoplasmic antibody mediated vasculitis (ANCA), C3 glomerulopathy, IgA nephropathy, immune complex ...
Peter F. Zipfel, Peter F. Zipfel, Thorsten Wiech, Ramona Rudnick, Sara Afonso, Fermin Person, Christine Skerka   +6 more
doaj   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

C3 Glomerulopathy: A Rare Entity with Future Directions

Revista Portuguesa de Nefrologia e Hipertensão, 2023
C3 glomerulopathies are a rare group of glomerular diseases resulting from excessive activation of the alternative complement pathway. The pathogenesis involves genetic, acquired, or immunologic defects in regulators of the alternative complement ...
Sara Vilela, Catarina Cardoso, Sara Barreto, Gonçalo Cruz, Pedro Bravo, Cristina Santos   +5 more
doaj   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source